GlycoVaxyn is a clinical stage biopharmaceutical company focused on the development and manufacture of next-generation bioconjugate vaccines utilizing its proprietary recombinant DNA technology.



 
07.08.14 GlycoVaxyn AG to Present at the 248th ACS National Meeting & Exposition in San Francisco, USA
01.07.14 GlycoVaxyn AG Announces the Initiation of a Phase I Clinical Trial in Collaboration with Janssen
12.06.14 GlycoVaxyn AG to Present at the FASEB Microbial Glycobiology Conference in Itasca, USA
 

GlycoVaxyn will be present during:

- 248th ACS National Meeting & Exposition in San Francisco on August 10-14, 2014

- FASEB Microbial Glycobiology Conference in Itasca on June 8-13, 2014

- IBC Bioconjugates Conference in San Francisco on June 4-6, 2014